Although the revenue and EPS for Inogen (INGN) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street es
Inogen, Inc. (NASDAQ:INGN ) Q2 2023 Earnings Conference Call August 7, 2023 4:30 PM ET Company Participants Agnes Lee - Senior Vice President, Investor Relations and Strategic Planning Nabil Shabshab
Inogen (INGN) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to loss of $0.02 per share a year ago.
Inogen's (INGN) latest acquisition is expected to leverage its commercial infrastructure and capabilities as well as potentially address a large growing bronchiectasis market.
Inogen's (INGN) revenue growth in the second quarter is likely to have been hampered by lower revenues in its business-to-business and direct-to-consumer channels.
Inogen's Q1 2023 results disappointed the market, despite management's confirmation that previously issued FY23E guidance remained unchanged. New product launches, including Rove 6 distribution in Eur
While the traditional approach to market success calls for patiently investing in reliable blue chips, those that want to see more immediate gains may consider small-cap stocks to buy. Here, the point
GOLETA, Calif.--(BUSINESS WIRE)--Inogen to Present at 43rd Annual William Blair Growth Stock Conference.
Inogen, Inc. (NASDAQ:INGN ) Q1 2023 Earnings Conference Call May 4, 2023 5:00 PM ET Company Participants Agnes Lee – Senior Vice President-Investor Relations and Strategic Planning Nabil Shabshab �
Despite higher domestic business-to-business sales and rental revenues, Inogen's (INGN) overall first-quarter results reflect soft performances.
While the top- and bottom-line numbers for Inogen (INGN) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to
Inogen (INGN) came out with a quarterly loss of $0.63 per share versus the Zacks Consensus Estimate of a loss of $0.77. This compares to loss of $0.38 per share a year ago.
GOLETA, Calif.--(BUSINESS WIRE)--Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that management wil
Investors continue to be optimistic about Inogen (INGN) on its potential in the POC space and a strong product portfolio.
Inogen (INGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE